Dineshkumar Patel
Interventional Cardiology · Melbourne, FLNPI 1316160161
Payments from drug & device makers
Across 314 payments — averaging $35.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abbott$2K
- Edwards Lifesciences$1K
- Novartis$776
- Boston Scientific$748
- Amgen$534
- plus $4K from 28 others
What the payments were for
- Travel & lodging$1,85517%
- Food & beverage$9,31883%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 36 | $1,834 |
| Abbott | 20 | $1,785 |
| Edwards Lifesciences | 14 | $1,399 |
| Novartis | 44 | $776 |
| Boston Scientific | 10 | $748 |
| Amgen | 30 | $534 |
| Johnson & Johnson | 17 | $353 |
| Shockwave Medical, Inc | 3 | $352 |
| Abiomed | 9 | $324 |
| Pfizer | 16 | $309 |
| AstraZeneca | 19 | $301 |
| Biotronik Inc. | 6 | $295 |
| Biosense Webster, Inc. | 4 | $280 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 15 | $239 |
| Boehringer Ingelheim | 9 | $225 |
| Merck | 13 | $208 |
| W. L. Gore & Associates, Inc. | 2 | $202 |
| Cvrx, Inc. | 12 | $195 |
| E.r. Squibb & Sons, L.L.C. | 7 | $120 |
| Celonova Biosciences, Inc. | 1 | $112 |
| Lexicon Pharmaceuticals, Inc. | 5 | $105 |
| Opsens Inc. | 3 | $81 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Actelion Pharmaceuticals US, Inc. | 2 | $57 |
| Daiichi Sankyo Inc. | 2 | $55 |
| Cardiva Medical, Inc. | 2 | $52 |
| Sanofi-aventis U.S. LLC | 2 | $42 |
| Siemens Medical Solutions USA, Inc. | 1 | $28 |
| Cardinal Health 200 LLC | 1 | $24 |
| Bayer | 1 | $20 |
| Acist Medical Systems, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$922
- Edwards SAPIEN 3 Transcatheter Heart Valve$447
- CoreValve Evolut$359
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$303
- TRICLIP$271
- SAPIEN 3 Ultra RESILIA$235
- MitraClip System$145
- GORE CARDIOFORM Septal Occluder$142
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$140
- AVVIGO Guidance System$138
- Watchman$125
- NUVISION ICE CATHETER$125
- BioMonitor$118
- MitraClip$112
- WATCHMAN FLX$112
How this compares
$11,187 in reported general payments places this provider in the 50th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 353 | $419,347 |
| EntrestoSacubitril/Valsartan | 171 | $226,958 |
| XareltoRivaroxaban | 99 | $111,378 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 81 | $23,484 |
| MultaqDronedarone Hcl | 14 | $22,127 |
| Praluent PenAlirocumab | 18 | $13,206 |
| BrilintaTicagrelor | 17 | $12,549 |
| Repatha SureclickEvolocumab | 11 | $12,300 |
| Metoprolol Succinate | 565 | $9,630 |
| Midodrine Hcl | 22 | $3,671 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 104 | $3,485 |
| PradaxaDabigatran Etexilate Mesylate | 15 | $3,122 |
| Dilt-XrDiltiazem Hcl | 61 | $2,943 |
| Losartan Potassium | 209 | $2,769 |
| Potassium Chloride | 53 | $2,671 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $309 | $419,347353 claims |
| NovartisEntresto | $776 | $226,958171 claims |
| Johnson & JohnsonXarelto | $353 | $111,37899 claims |
| Sanofi-aventis U.S. LLCMultaq | $42 | $22,12714 claims |
| AstraZenecaBrilinta | $301 | $12,54917 claims |
| Boehringer IngelheimPradaxa | $225 | $3,12215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Melbourne
- Dominick AngiolilloJacksonville$4M
- Douglas SpriggsClearwater$3.2M
- Rakesh PrashadOcala$3.1M
- Aldo Martinez FleitesMiami Lakes$2.2M
- Rohit AminPensacola$2M
- Roberto CubedduNaples$2M
- Arthur LeeGainesville$2M
- Ruby SatpathyJacksonville$1.8M
- Santhosh MathewsBradenton$1.7M
- Pedro Martinez-ClarkMiami$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.